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creativecommons.org/licenses/by-nc-nd/Abstract Background: In this study, building on our recent work identifying a subset of
CD66þve cells with distinctive tumourigenic properties in human cervical cancers, we examine
patterns of expression and function of these cells; to generate insights into the process of
metastasis.
Methods: Our broad approach in this study has been to compare the expression and function
of two subsets marked by CD66 and CD49f. We use a combination of histopathology, immu-
nostaining and flow cytometry, functional analysis of an established cervical cancer cell line
and a retrospective analysis of a cohort of cervical cancer.
Results: We noted CD66 expression associated with clusters of cells which are spindle shaped,
SMAþve, podoplaninþve, phalloidin high, fibronectin high, plakoglobin low, ki67ve and
CK10þve at the migratory phase along with features of partial EMT. Further, TGFb1 a well
known regulator of EMT, positively correlated with CD66 expression. The additional
CD49fþve subset at the leading invading front of migration was SMAve, phalloidin low,
fibronectin low, plakoglobin high, Ki67þve and CK14þve. These data are consistent with ana, National Centre for Biological Sciences, TIFR, UAS-GKVK Campus, Bellary Road, Bangalore,
ax: þ91 80 23636662.
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A. Ammothumkandy et al. / European Journal of Cancer 60 (2016) 166e178 167role for CD66 cells in metastatic invasion with a collective cell migration process co-opting the
CD49f subset. Our retrospective analysis of a cohort is consistent with a role for CD66 in
metastasis. However, the broad analysis of CD66, CD49f and TGFb1 expression with patterns
of overall survival points to a possible protective effect particularly for local recurrences.
Hence, future studies focussing on potential heterogeneity within the CD66 subset along with
the possible role of isoforms and intra-cellular roles would be essential.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
An ongoing challenge in cancer biology is to understand
how distinct tumourigenic subsets mediate progression of
human cancers [1]. In particular, the mechanisms and
contribution of Epithelial to Mesenchymal Transition
(EMT), the linkage with chemo resistance, and the stage
specific role of such subsets are currently poorly under-
stood phenomena. The CD66 gene is a part of the carci-
noembryonic antigen related cell adhesion molecule
(CEACAM) family with various splice variants, amongst
which CD66a, c and e are highly expressed in several
cancers and have been suggested to mediate poor out-
comes in some instances [2e5]. We have recently charac-
terised a subset of CD66þve cells in cancers [6] and pre-
cancers [7] of cervix with distinctive tumourigenic prop-
erties. While invasiveness of CD66þ cells in both cervical
pre-cancer and cancers seems a hallmark of this subset,
there are parallel complex observations on the differenti-
ation andcell cycle status of this subsetwhichhasmade the
generation of simplistic models of tumourigenic progres-
sion somewhat difficult. Recent studies on breast cancer
progression draw attention to the need to look at multiple
subsets, and possibly gene expression along with differ-
entiation in the setting of collective cell migration [8e10],
as this might be pathophysiologically more relevant.
The other specific subsets in human cervical cancer
that have been identified include CD49fþ cells, which
have been suggested to be tumour initiating cells by
some investigators [11e13]. CD49f is expressed in the
basal layer of normal cervix and is present even in the
upper layers of ectocervical epithelium in cervical
intraepithelial neoplasia [14]. CD49f and its interacting
partners have also shown to have an association with
invasion [15e21] across tumours and is a plausible
marker for a basal cell that can lead collective invasion.
In addition to analysing the role of specific subsets, it is
critical to examine putative signalling modulators, such
as TGFb. TGFb has shown to have both growth
inhibiting and EMT inducing roles [22,23] in a range of
cancers. From other reports in cervical cancer, TGFb is
associated with less tumour infiltration and a tumour
suppressor function [24,25].
In a clinico-pathological perspective of collective cell
migration, tumour sections have shown presence ofsarcomatoid cells, with the suggestion that these cellular
clusters drive metastasis and drug resistance [26,27]. Such
sarcomatoid cells are infrequently found in human car-
cinomas and appear as bundles of spindle like or giant
multinucleated cells marked by the expression of smooth
muscle actin (SMA) and podoplanin. In addition, they
have features of partial EMT i.e. expressing both E and
N-cadherin, often referred to as metastable cells [28].
In this study, we analysed the expression of CD66 in
sarcomatoid like clusters of cells in primary human
cervical cancers along with CD49fþ cells. We developed
assays for collective invasion of a human cervical cancer
cell line, and also assessed the role of CD66/CD49f
subsets. Following the characterisation of sarcomatoid
cells, we explored the role of TGFb1 and its association
with CD66 expression and possible metastatic out-
comes. In addition to a functional analysis of an
established human cervical cancer cell line, we examined
CD66, CD49f and TGFb1 expression in a cervical
cancer patient cohort with known clinical outcomes.
The study attempts to address the question of whether
there is possible heterogeneity in the CD66þ subset in
terms of clinical significance, as this would lay the
foundation for an analysis of CD66 isoforms, intra-
cellular roles, possible stage specific roles linked to dif-
ferentiation etc.
2. Materials and methods
2.1. Collective invasion assay with spheres in matrigel
The cell line CaSki, obtained from ATCC was cultured
as spheroids for 14 days as previously described [6].
Spheroids were collected in sphere media, mixed with
equal amount of matrigel and seeded in confocal dishes
such that spheroids were spaced far apart. Sphere media
was added after the matrigel solidified. After 30 hrs, cells
were fixed with 4% PFA for 20 min. 3 PBS washes were
given for 10 min each. Regular IF protocol was followed
with all incubation time points 3 times.
2.2. Clinical sample processing
Primary human cervical SCC biopsy samples processed
as previously described [6]. Cells were lineage depleted
Fig. 1. CD66 expression is associated with collectively invading tumour clusters and CD49f at the invasive front in human cervical cancer.
A) C13 tumour section shows cells with sarcomatoid morphology (encircled with dotted lines). The sarcomatoid cells have either spindle
shape morphology or giant multi-nuclei (black arrows) compared to the typical rounded carcinoma cells (white arrows). 40 Magnifi-
cation B) CD66, CD49f, E-cadherin and N-cadherin expression in spindle and rounded cells at 40 magnification. Sarcomatoid like
phenotype was observed only in 2/11 cases examined. The serial sections of these sarcomatoid like cells show higher expression of both
epithelial marker E-cadherin and mesenchymal marker N-cadherin. C) Serial sections of tumour with sarcomatoid cells show that the
CD66þve sarcomatoid cells are positive for SMA and podoplanin. D) Staining of CD66 and CD49f in sections with early phases of
invasion into the basal lamina shows CD49fþ (red) at the invading edge and CD66þ (green) cells present in the differentiated top layers.
The dotted line separates the epithelial and dermal layer. The arrow denotes the direction of invasion (nZ 4). Scale bar 50 mm. E) CaSki-
spheroids embedded in matrigel invade collectively with finger-like protrusions. F, G) Grey scale and overlapping images showing the
invasion fingers express CD49f (orange) at the leading front and CD66 (green) at the trailing cells. Dotted line shows the outer boundary
for invading cells .Scale bare 50 mm. Figure F, G are representative images from a minimum of 3 independent experiments.
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analysed by FACS. Biopsy samples were labelled as C e
a number (in serial order).3. Results
3.1. CD66 expression is associated with collectively
invading tumour clusters and CD49f at the invasive front
in human cervical cancer
We examined the expression of CD66 and CD49f in the
context of invading cells in primary cervical cancer. We
searched for clusters of cells that may be putative sar-
comatoid cells in cervical squamous cell carcinoma
(SCC’s) (nZ 11). Sarcomatoid like cells were identified
in 2/11 cases with the typical morphology of spindle like
cells in collective bunches with few giant nuclei
(Fig. 1A). We further undertook immunostaining of
these cells for CD66 and CD49f along with some of the
markers known to be co-expressed in a typical sarco-
matoid cell e E-cadherin, N-cadherin, SMA and
podoplanin (Figs 1B,C, and S1A). These clusters were
E-cadherin, N-cadherin, SMA, podoplanin and
CD66þve.They expressed lower levels of CD49f
compared to normal carcinoma cells. Thus sarcomatoid
like cells have features of partial EMT, consistent with a
role in metastatic progression.
To examine CD66 and CD49f in the context of col-
lective cell migration, we examined regions that are
likely to represent the initial invasive phase in primary
SCC’s along with CaSki cells undergoing collective cell
migration. CaSki-spheroids are heterogeneous for CD66
and CD49f expression with around 20, 14, 7, 59 per-
centages of CD66þCD49f, CD66CD49fþ,
CD66þCD49fþ and CD66CD49f subsets respec-
tively in a 14 day spheroid culture (Fig. S1B). We
assessed the invasive cell clusters which were prominent
after 30 hrs of culturing CaSki spheroids in matrigel
(Fig. 1E). The invasive cells expressed both epithelial
marker E-cadherin and mesenchymal markers N-cad-
herin and vimentin (Fig. S1C). In the context of both
initial invasive phases of SCCs (Fig. 1D) and CaSki
invasion assay, CD49f cells are ahead of CD66 cells in
the advancing invasive zone (Fig. 1F,G). These data
show that CD49f expressing cells are present at the
invasive front of collectively invading CD66þve tumour
clusters.3.2. CD49f and CD66 subsets associated with distinct
neoplastic traits
Having noted that CD66 and CD49f expression is
segregated into different cells in invading clusters, we
explored their functional traits. We use cytokeratin and
ki67 staining to assess the basal and proliferative po-
tential of these cells. The features of migration and EMTwere evaluated by staining for phalloidin, SMA, fibro-
nectin and plakoglobin. These markers were evaluated
along with CD66 and CD49f in CaSki invasive pro-
trusions. CK14 (basal) and CK10 (differentiation)
expression was present at the leading and trailing com-
partments respectively (Fig. 2A). A greater number of
ki67þve cells were present in the leading front (Fig. 2B)
compared to the trailing region. Trailing cells were
marked by high phalloidin (Figs. 2C and S2), high
fibronectin and low plakoglobin expression (Fig. 2D).
As we find enhanced features of EMT and migration in
the trailing cells, we proposed the leading edge to be
more like a growing/proliferating edge of the advancing
tumour. In order to look at spatiotemporal progression,
we also undertook phalloidin and CD49f staining at the
zones proximal to CaSki spheroids which are regions of
likely initiation of invasion (Fig. 2E). We find increased
expression of CD49f in these regions along with stronger
phalloidin staining as the cells initially invade out of
spheroid (Fig. 2E,F).
Further, tumours with features of early invasion
show higher expression of SMA in differentiated trailing
edges in comparison to leading edges (Fig. 2G). Further,
the basal regions of stratified epithelium had greater
numbers of ki67þve cells in both normal cervix
(Fig. 2H) and in SCC sections (Fig. 2I). Similarly,
expression of CD49f was high in the basal region of
cervical neoplasms and was absent towards differenti-
ated regions (Fig. 2J). Further, we looked at sarcoma-
toid cells in SCC and observed that these cells are
CD66þve and ki67ve, whereas non sarcomatoid
tumour cells around are CD66ve and Ki67þve
(Fig. 2K). Collectively, our observations in Fig. 2 show
that both in primary tissue and cervical cancer cell line
model, the leading CD49f positive cells are more basal
and proliferative; whereas trailing CD66 cells are
more differentiated, migratory and show features of
EMT. We have previously shown[7] using dye-dilution
experiments that in whole CaSki-spheroids, CD66
CD49fþcells proliferate more compared to other sub-
sets. Also we have shown [7] that CD66 and CD49f
subsets follow a hierarchy in the expression of differ-
entiation markers S100P and Involucrin in sorted cells
from cell line and patient samples. CD66þCD49f cells
express highest levels of S100P and involucrin, followed
by CD66þCD49fþ cells and then the CD66CD49fþve
cells.
3.3. CD66 and CD49f subsets from entire tumours also
show distinctive traits
In Figs 1 and 2, we used histopathology on invasive
zones and demonstrated the distinct localisation and
function of CD66 and CD49f subsets. We further eval-
uated if the properties of CD66 and CD49f cells are
retained in the bulk of the tumour cells. We measured
proliferation (by Ki67) and EMT associated markers in
Fig. 2. CD49f and CD66 subsets associated with distinct neoplastic traits. A) The leading edge outer cells show expression of high basal
associated Cytokeratin CK14 (green) and low differentiation associated Cytokeratin CK10 (green) in contrast to trailing cells. B) The
leading edge has more ki67þve cells (red) a marker for proliferating cells compared to trailing cells which express CD66 (green). C) The
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tumour biopsies using flow cytometry. Ki67 and Oct4
(pluripotency marker) high cells from CaSki-spheroids
showed higher expression of CD49f (Fig. 3A,B). We
also observe that the chemotherapeutic drug-Cisplatin
reduces the proliferative CD49fþve pool from CaSki
spheroids (Fig. 3C). The analysis of CaSki-spheroids
(Fig. S3A,C) and lineage-depleted tumour cells from
patient biopsies C50 and C51 (Figs 3D,E, and S2B,D)
reveal that CD66þve cells from bulk tumour cells have
features of partial EMT, measured by higher expression
of all the three proteins e E-cadherin, N-cadherin and
vimentin. Collectively from Figs. 1,2,3AeE, we find a
striking correlation of CD49f and CD66 subsets with
proliferation and partial EMT respectively.
Having characterised the functional properties of
CD66 and CD49f subsets, we proceeded to explore their
possible clinical implications. We evaluated the inter-
tumour heterogeneity of CD66 and CD49f expression
from primary cancers. Biopsies of primary cervical
cancer showed different ratios of CD66 and CD49f
when analysed by flow-cytometry at the time of first
clinical presentation (Fig. 3F). There is an intriguing
association of CD66 expression (Fig. 3F) and the pres-
ence of sarcomatoid cells (2 cases with sarcomatoid cells
mentioned in Fig. 1A are samples C13 and C14). The
extensive heterogeneity of CD66 and CD49f expression
led us to search for possible signature cues which would
induce these phenotypes.
3.4. TGFb, an EMT signaling pathway is associated with
higher CD66 to CD49f subset ratios
TGFb1 has been previously shown to induce EMT in
wide range of human cancers. We therefore explored the
link between CD66 and CD49f expression with TGFb1
levels. We analysed the expression of TGFb1 and a key
downstream intermediate pSmad3 in SCC sections (Figs
4A and S7) and compared with the CD66 and CD49f
expression in the same samples as analysed by FACS
(Fig. 3F). Across patient samples the tumours (C13)
with highest fraction of CD66þCD49f subset (Fig. 3F)
shows increased levels of TGFb1 and nuclear pSmad3
expression (Fig. 4A). CD66þve subset showed a clear
correlation with TGFb1 score (Fig. S4A).
CD66þCD49f subset had a stronger positive correla-
tion (Fig. 4B) with TGFb1 score. Consistent with thesetrailing CD66þCD49f cells (red) are high for phalloidin (green) stain
levels of phalloidin. D) The trailing cells show features of EMT like hi
Representative image of spheroid invasion assay. Red box denotes th
denotes zones closer to spheroid where cells start to invade. F) CD49
increase in CD49f expression as phalloidin fibers start to appear. The
experiments. Scale bar e 50 mm. G) Early invasions in SCCs show ex
separates the dermal and epidermal layer. H, I) Cervical stratified epith
normal cervix and I) SCC. J) Basal region of stratified epithelium sh
images of observations from a minimum of 4 different patient sectionresults, in vitro induction of EMT in CaSki-spheroids by
TGFb1 treatment for 72 hrs increased the CD66þ
CD49f subset and decreased CD66CD49fþ subset
(Figs 4C and S4C). There was a concomitant increase in
migration property (Fig. 4D) as measured in a transwell
assay. TGFb1 treatment also induced a cell proliferation
arrest as measured by WST-cell proliferation assay
(Fig. S4B) and clonogenic assays (Fig. 4E). Collectively
the data from Fig. 1e4 show a consistent association of
CD66 subset migration and posit TGFb1 as a potential
inducer.
3.5. Human cervical cancer metastasis is associated with
high CD66, TGFb1 and CD49f expression
We further looked at association of CD66 and CD49f in
reported cases of lymph node metastasis. The staining
suggested that all the 4/4 cases with lymph node
metastasis expressed high levels of CD66 and CD49f in
the primary tumour site (Fig. 5A). To further analyse
subsets that are enriched in the lymph node metastasis
we performed CD66 and CD49f staining in their
respective matched lymph node tumour section. In all
the 4 cases the expression of CD66 and CD49f was high
and also they followed a similar pattern as that of pri-
mary tumour (Figs 5B and S8). This data is consistent
with a functional role for CD66 in metastasis with a
possible supportive role for CD49fþve cells. In Table 1
we show a similar pattern of high CD66, TGFb1 and
CD49f scores associated with distant metastatic out-
comes observed in a different larger cohort study.
Collectively high CD66 and CD49f expression is asso-
ciated with both lymph node and distant-metastasis.
Our model of cervical cancer invasion in which
distinct tumour subsets CD66 and CD49f with proper-
ties of migration and proliferation respectively driving
tumour progression is presented in the graphical
abstract.
3.6. CD66 and TGFb 1 positive tumours are associated
with better overall survival
We were further interested in two aspects of CD66
expression in terms of clinical outcomes- whether the
diverse clinical outcomes correlate with CD66 expres-
sion and if it can be measured by broad CD66 expres-
sion in tumour sections. The cohort consisted of 153ing and leading edge CD66CD49fþ cells (orange) express lower
gh fibronectin and low plakoglobin, compared to leading cells. E)
e region of invasive protrusion studied in Fig. 2AeD, Blue box
f and phalloidin staining in zones closer to spheroid showing an
Fig. 2AeF are representative images of minimum 3 independent
pression of SMA (red) in differentiated trailing end. Dotted line
elium shows more of ki67þve cells towards the basal layers of H)
ows higher CD49f expression. The Fig. 2GeJ are representative
s. K) CD66þve sarcomatoid cells in SCC sections are ki67ve.
Fig. 3. Properties and ratios of CD66 and CD49f cells in the bulk tumour. A) Ki67 high cells in CaSki spheroids are CD49f high. B) Oct4
high cells in CaSki spheroids are CD49f high. (A, B. Representative plot minimum of 3 biological replicates in CaSki spheroids). C)
Percentage of CD66 and CD49f fractions with and without Cisplatin treatment for 24 hrs on CaSki 14 day spheroid (nZ 3). D)
CD66þCD49fþ and CD66þCD49f subsets in primary cervical cancer biopsies express both epithelial (E-cadherin) and mesenchymal
markers (N-cadherin and vimentin) at a higher level as shown by histograms derived from FACS analysis and E) quantification of mean
fluorescence intensity of E, N-cadherin and vimentin across CD66 and CD49f subsets. Error bars correspond to nZ 3 technical replicates
of the same patient. F) Frequency analysis of CD66 and CD49f subsets by flow cytometric analysis in cells isolated from primary cervical
cancer biopsy after lineage depletion (nZ 25). Samples marked with * on the top are the 2 samples with sarcomatoid cells mentioned in
Fig. 1A. Sample names boxed with red are stained for TGFb1 and pSmad3 in Fig. 4
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Fig. 4. TGFb, an EMT signalling pathway is associated with higher CD66 to CD49f subset ratios. A) TGFb1 and pSmad3 expression by
IHC in representative patient samples show greater level of both these proteins in C13 sample which has the highest percentage of
CD66þCD49f subset. TGFb1 staining is performed in nZ 11 patient sections and pSmad3 in nZ 6 patient sections. The images shown
are from patients C13, C14, C32, C41 which are from biopsies having high percentages of CD66þCD49f, CD66þCD49fþ,
CD66CD49fþ, CD66CD49f subsets respectively as shown in Fig. 3D (boxed in red). Scale bar 50 mm. B) The percentage of
CD66þCD49f subset in primary cervical cancer biopsies (nZ 11) as analysed by flow cytometry shows positive correlation with TGFb1
IHC score. Pearson’s correlationZ 0.83, pZ 0.001362. C) Treatment of CaSki-spheroids with 2 ng/ml TGFb1 growth factor for 72 hrs
expands the CD66þCD49f subset and reduces the CD66CD49fþ subset. Minimum 3 biological replicates. D) Treatment of CaSki-
spheroids with TGFb1 increases the migration potential of these cells as measured by a Boyden chamber assay. Experiment biologi-
cally replicated twice with 3 technical replicates. p value in Fig. 4C and D determined by student’s t test, and two tailed. E) CaSki spheroid
cells in clonogenic assay after 10 days shows an arrest in cell proliferation with continuous TGFb (2 ng/ml) treatment. Representative
image from 3 biological replicates.
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treatment and had a follow-up of 7 years or more. Of
the 153 patients studied, 55 cases failed in the primary
line of treatment, principally radiotherapy. Out of the
55 cases with poor outcome, 7 developed distant-
metastasis (Table 1) and 36 had either partial response
with treatment followed by progression or developed
local relapse after achieving apparent complete clinical
remission (Fig. 6A). In addition, there were 12 cases
with unknown cause of death all of whom were pre-
sumed to have been lost to disease. This data is
consistent with the clinical paradigm that loco-regional
failure is the major cause of poor clinical outcomes in
cervical cancer.We analysed the immuno-histochemical expression of
CD66, CD49f and TGFb1 and correlated it with clinical
outcomes (Fig. 6 and Table 2).Patients with TGFb1
expressing tumours had the best outcome with 91/133
being free of disease, while amongst the TGFb negative
tumours 7/20 only were free of disease (Fig. 6E,H).
Patients with CD66þ tumours had better outcome
compared to CD66 tumours (Fig. 6B). Of the 115
CD66þ cases 79 were disease free compared to 19/38
cases being disease free in the CD66 cases. CD49fþ
and CD49f tumours showed similar survival pattern
(Fig. 6C). TGFb in association with CD66 or CD49f
was found to predict a better outcome albeit at a lower
significant level, suggesting that the main effect was
from TGFb expression (Fig. S6). CD66, CD49f dual
Fig. 5. Human cervical cancer metastasis is associated with high CD66, TGFb1 and CD49f expression. A) Primary biopsies for tumours
which showed lymph node positive metastatic tumours have high expression of both CD66 and CD49f in all the 4 cases studied. B)
Matching lymph node sections for these tumours also show high expression of CD66 and CD49f.
Table1
Scores for CD66, CD49f and TGFb in all the cases of distant-
metastasis in retrospective study
Biopsy no. CD66
score
CD49f
score
TGF
beta1
score
Disease
free
survival
Overall
survival
Metastasis
4249/02 5 6 5 50 113 Lung and
liver
5432/02 6 4 4 13 20 Lung
6562/02 4 7 3 5 5 Lung
4526/02 4 7 4 39 46 Bone
5558/02 0 7 0 6 16 Bone
892/02 5 6 5 31 38 Lung
1015/02 6 0 4 43 65 Lung
A. Ammothumkandy et al. / European Journal of Cancer 60 (2016) 166e178174positive cases showed better DFS and OS compared to
other permutations of expression (Fig. 6D,G).
Concomitantly, the CD66, CD49f, TGFb1triple positive
cases also had a better survival advantage (Fig. 6F,I).
DFS data is included in the supplementary (Fig. S5,S9).
In early stage cervical cancer (nZ 18), none of the
CD66/CD49f double positives (nZ 9) failed to respond
to treatment, whereas lack of expression of either CD66
or CD49f (nZ 9), had 4 failures. In late stage CD66/
CD49f double positives tumours 28/86 where associated
with failures (Fig. 6J). Overall CD66 and TGFb1 posi-
tive tumours (Fig. 6B,E) were associated with better
overall survival possibly due to the bias imposed by
Fig. 6. CD66 and TGFb 1 positive tumours are associated with better overall survival. A) The patients with poor outcome belong majorly to local-recurrence. BeF) KaplaneMeier curves for
overall survival (OS) in SCCof cervix (NZ 153) shows: B) according to CD66 expression status alone, statistically significant increase inOSwas observed in CD66 positive tumours (pZ .011).
C) According to CD49f expression status, no statistically significant increase in OS was observed in CD49f positive tumours ( pZ .614). D) According to CD66/CD49f double positive
expression status, statistically significant increase in OS was observed in CD66/CD49f double positive tumours (pZ .041). E) According to TGF-b expression status, statistically significant
increase inOSwas observed in TGF-b positive tumours (pZ .000). F) According toCD66/CD49f/TGF-b triple positive expression status, statistically significant increase inOSwas observed in
CD66/CD49f/TGF-b triple positive tumours (pZ .002). GeI) Distribution of outcome and expression in 153 patients and their significance with chi square test: G) CD66/CD49f dual
expression tends to correlate withNo evidence of disease (NED) compared to when expressed alone (pZ .059). H) TGFb expression correlates with more chances of NED (pZ .004). I) CD66/
CD49f/TGFb triple positives have higher correlation with NED (.002). J) Distribution of outcome and expression for CD66 and CD49f in early versus late stage tumour (pZ .024).
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Table2
Cox prognostic factors by vital status (Overall survival) CD66, CD49f and TGFb1 in 153 cases of human cervical SCCs.
Cox prognostic factors by vital status (Overall survival)
Univariate analysis Multivariate analysis
Variables Factors Cases HR 95% CI p Value HR 95% CI p Value
CD66 Positive 115 1.00a 1.00a
Negative 38 1.976 1.154 e 3.385 .013* 1.991 1.142 e 3.471 .015*
CD49f Positive 131 1.00a 1.00a
Negative 22 1.19 .604 e 2.347 .615 1.288 .627 e 2.644 0.491
TGFb1 Positive 133 1.00a 1.00a
Negative 20 2.88 1.576 e 5.264 .001* 2.536 1.373 e 4.682 .003*
CD66 and CD49f double positive Positive 95 1.00a 1.00a
Negative 58 1.686 1.015 e 2.801 .044* 1.708 1.025 e 2.847 .040*
CD66,CD49f and TGFb1 positive Positive 86 1.00a 1.00a
Negative 67 2.205 1.318 e 3.688 .003* 2.179 1.300 e 3.653 .003*
a Reference category.
* Z p< 0.05.
A. Ammothumkandy et al. / European Journal of Cancer 60 (2016) 166e178176local recurrences which is the major cause of treatment
failure.4. Discussion
In this study, we have addressed three inter-related
questions i) Given the focus on migration from previous
studies on CD66þ cells, what are the mechanistic in-
sights that emerge on a more detailed analysis of this
particular function? ii) Are there distinctive expression
profiles and concomitant functional properties for
CD66þ and CD49þ cells iii) Do the clinical outcomes
assessed largely based on expression profiles of CD66
provide insights into the emergence of both metastasis
and local recurrence ?
In this study, we identify clusters of CD66 cells which
based on the features of partial EMT, migration,
morphology and non-proliferative state that are
consistent with a role in metastasis. Such sarcomatoid
cells are difficult to detect across cancers and their
mechanistic role in driving human tumour progression is
of enormous interest. Our observations in this study are
consistent with more complex models of migration being
associated with tumour progression in the form of col-
lective cell migration [29e31]. In particular, our data
reveals two distinct CD66 and CD49f subsets in both
primary cancers and established cell lines and imply that
therapeutic targeting might require a synergistic
approach to address issues of proliferation and migra-
tion simultaneously. This is likely to be further compli-
cated by the plasticity that we also potentially detect in
the emergence of CD49f subsets over the various phases
of collective cell migration (Fig. 2F). Our observation of
CD66CD49fþ leader cells is in keeping with the
literature which posits basal cells at the leading edge [8].
However, with respect to migration, contrary to other
studies the leading edge CD66CD49fþ cells have
reduced actin organisation but enhanced proliferativepotential in comparison to the trailing edge. Therefore
we consider this as collective invasion with growing edge
as CD49f cells had an association with proliferation.
Similar observations are reported in the case of
morphogenesis in mammary tissue where cellular ex-
tensions or actin rich protrusions are absent in the front
of advancing mammary ducts; but present in the luminal
side [30]. Expression of CD49f at the leading edge in-
creases as the phalloidin rich invasion protrusions
become more prominent (Fig. 2E,F).This might suggest
two points: 1) that cells switch to CD49fþ cells as they
invade out and attach to the substrate. 2) as there is an
increase in phalloidin stress fibers with increase in
CD49f expression with growing cell protrusions; it’s
likely that CD49f expression at the leading edge might
be essential for making the cells behind more migratory
[15,32,33].
Our flow cytometry analysis of primary cancers was
only partially revealing; in the absence of clinical
outcome information from that particular cohort. It
does however suggest a link with high CD66 expression
and sarcomatoid cells and further validate the EMT
profiles that we obtained by immunostaining as shown
by association with TGFb. Tumourigenic progression is
clearly dependent on signals such as TGFb and they
have not been easy to resolve conclusively given the
plethora of studies which have shown both a pro-
oncogenic and tumour suppressive role for this
pathway [22]. The data presented in this study is
consistent with a link between CD66 and TGFb
expression. However, the cohort analysis based on
broad expression patterns of CD66, CD49f and TGFb
reveal that the expression correlates that we see with
metastatic samples (from different centers) does not
necessarily lend itself to an easy explanation for local
recurrences. Even well studied CD44þve CD24ve
breast cancer stem cell subset has shown to be not
associated with OS, but favouring distant metastasis
[34]. It is likely that there might be different subsets of
A. Ammothumkandy et al. / European Journal of Cancer 60 (2016) 166e178 177CD66 with differentiation status or that there is het-
erogeneity based on isoforms. Also the significance of
intra-cellular staining of CD66 observed in the retro-
spective study remains to be explored. In conclusion,
while we provide a both mechanistic and clinical insight
into the role of CD66 in human cervical cancer invasion
and metastasis, this study emphasises that there might
be diverse mechanisms of progression of local re-
currences which are still poorly understood.
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